News | April 04, 2026
BASF Pharma Solutions announces up to 20% price hike on excipients and APIs
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
This marks a meaningful step in the company's continued expansion in the region
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Subscribe To Our Newsletter & Stay Updated
